Measles-derived vaccines to prevent emerging viral diseases.
Identifieur interne : 000A28 ( PubMed/Curation ); précédent : 000A27; suivant : 000A29Measles-derived vaccines to prevent emerging viral diseases.
Auteurs : Phanramphoei N. Frantz [Thaïlande] ; Samaporn Teeravechyan [Thaïlande] ; Frédéric Tangy [France]Source :
- Microbes and infection [ 1769-714X ]
Descripteurs français
- KwdFr :
- Animaux, Humains, Maladies transmissibles émergentes (), Maladies virales (), Maladies virales (immunologie), Vaccin contre la rougeole (génétique), Vaccin contre la rougeole (immunologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins atténués (administration et posologie), Vaccins atténués (génétique), Vaccins atténués (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (génétique), Vaccins synthétiques (immunologie), Vecteurs génétiques (génétique), Virus (immunologie).
- MESH :
- administration et posologie : Vaccins atténués, Vaccins synthétiques.
- génétique : Vaccin contre la rougeole, Vaccins antiviraux, Vaccins atténués, Vaccins synthétiques, Vecteurs génétiques.
- immunologie : Maladies virales, Vaccin contre la rougeole, Vaccins antiviraux, Vaccins atténués, Vaccins synthétiques, Virus.
- Animaux, Humains, Maladies transmissibles émergentes, Maladies virales.
English descriptors
- KwdEn :
- Animals, Communicable Diseases, Emerging (prevention & control), Genetic Vectors (genetics), Humans, Measles Vaccine (genetics), Measles Vaccine (immunology), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (genetics), Vaccines, Attenuated (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Viral Vaccines (genetics), Viral Vaccines (immunology), Virus Diseases (immunology), Virus Diseases (prevention & control), Viruses (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, Attenuated, Vaccines, Synthetic.
- chemical , genetics : Measles Vaccine, Vaccines, Attenuated, Vaccines, Synthetic, Viral Vaccines.
- genetics : Genetic Vectors.
- chemical , immunology : Measles Vaccine, Vaccines, Attenuated, Vaccines, Synthetic, Viral Vaccines, Virus Diseases, Viruses.
- prevention & control : Communicable Diseases, Emerging, Virus Diseases.
- Animals, Humans.
Abstract
Infectious disease epidemics match wars and natural disasters in their capacity to threaten lives and damage economies. Like SARS previously and Zika recently, the Ebola crisis in 2015 showed how vulnerable the world is to these epidemics, with over 11,000 people dying in the outbreak. In addition to causing immense human suffering, these epidemics particularly affect low- and middle-income countries. Many of these deadly infectious diseases that have epidemic potential can become global health emergencies in the absence of effective vaccines. But very few vaccines against these threats have been developed to create proven medical products. The measles vaccine is an efficient, live attenuated, replicating virus that has been safely administered to 2 billion children over the last 40 years, affording life-long protection after a single dose. Taking advantage of these characteristics, this attenuated virus was transformed into a versatile chimeric or recombinant vaccine vector with demonstrated proof-of-principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. Clinical trials have shown the safety and immunogenicity of this vaccine platform in individuals with preexisting immunity to measles. This review describes the potential of this platform to develop new vaccines against emerging viral diseases.
DOI: 10.1016/j.micinf.2018.01.005
PubMed: 29410084
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A28
Links to Exploration step
pubmed:29410084Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Measles-derived vaccines to prevent emerging viral diseases.</title><author><name sortKey="Frantz, Phanramphoei N" sort="Frantz, Phanramphoei N" uniqKey="Frantz P" first="Phanramphoei N" last="Frantz">Phanramphoei N. Frantz</name><affiliation wicri:level="1"><nlm:affiliation>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France; Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France; Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani</wicri:regionArea></affiliation></author><author><name sortKey="Teeravechyan, Samaporn" sort="Teeravechyan, Samaporn" uniqKey="Teeravechyan S" first="Samaporn" last="Teeravechyan">Samaporn Teeravechyan</name><affiliation wicri:level="1"><nlm:affiliation>Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani</wicri:regionArea></affiliation></author><author><name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name><affiliation wicri:level="1"><nlm:affiliation>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France. Electronic address: ftangy@pasteur.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2018 Oct - Nov</MedlineDate></PubDate></date><idno type="RBID">pubmed:29410084</idno><idno type="pmid">29410084</idno><idno type="doi">10.1016/j.micinf.2018.01.005</idno><idno type="wicri:Area/PubMed/Corpus">000A28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A28</idno><idno type="wicri:Area/PubMed/Curation">000A28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Measles-derived vaccines to prevent emerging viral diseases.</title><author><name sortKey="Frantz, Phanramphoei N" sort="Frantz, Phanramphoei N" uniqKey="Frantz P" first="Phanramphoei N" last="Frantz">Phanramphoei N. Frantz</name><affiliation wicri:level="1"><nlm:affiliation>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France; Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France; Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani</wicri:regionArea></affiliation></author><author><name sortKey="Teeravechyan, Samaporn" sort="Teeravechyan, Samaporn" uniqKey="Teeravechyan S" first="Samaporn" last="Teeravechyan">Samaporn Teeravechyan</name><affiliation wicri:level="1"><nlm:affiliation>Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani</wicri:regionArea></affiliation></author><author><name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name><affiliation wicri:level="1"><nlm:affiliation>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France. Electronic address: ftangy@pasteur.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris</wicri:regionArea></affiliation></author></analytic><series><title level="j">Microbes and infection</title><idno type="eISSN">1769-714X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Genetic Vectors (genetics)</term><term>Humans</term><term>Measles Vaccine (genetics)</term><term>Measles Vaccine (immunology)</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (genetics)</term><term>Vaccines, Attenuated (immunology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (genetics)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term><term>Virus Diseases (immunology)</term><term>Virus Diseases (prevention & control)</term><term>Viruses (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Maladies transmissibles émergentes ()</term><term>Maladies virales ()</term><term>Maladies virales (immunologie)</term><term>Vaccin contre la rougeole (génétique)</term><term>Vaccin contre la rougeole (immunologie)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins atténués (génétique)</term><term>Vaccins atténués (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (génétique)</term><term>Vaccins synthétiques (immunologie)</term><term>Vecteurs génétiques (génétique)</term><term>Virus (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Attenuated</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Measles Vaccine</term><term>Vaccines, Attenuated</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins atténués</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genetic Vectors</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Vaccins synthétiques</term><term>Vecteurs génétiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Maladies virales</term><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Vaccins synthétiques</term><term>Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Measles Vaccine</term><term>Vaccines, Attenuated</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term><term>Virus Diseases</term><term>Viruses</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Maladies transmissibles émergentes</term><term>Maladies virales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infectious disease epidemics match wars and natural disasters in their capacity to threaten lives and damage economies. Like SARS previously and Zika recently, the Ebola crisis in 2015 showed how vulnerable the world is to these epidemics, with over 11,000 people dying in the outbreak. In addition to causing immense human suffering, these epidemics particularly affect low- and middle-income countries. Many of these deadly infectious diseases that have epidemic potential can become global health emergencies in the absence of effective vaccines. But very few vaccines against these threats have been developed to create proven medical products. The measles vaccine is an efficient, live attenuated, replicating virus that has been safely administered to 2 billion children over the last 40 years, affording life-long protection after a single dose. Taking advantage of these characteristics, this attenuated virus was transformed into a versatile chimeric or recombinant vaccine vector with demonstrated proof-of-principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. Clinical trials have shown the safety and immunogenicity of this vaccine platform in individuals with preexisting immunity to measles. This review describes the potential of this platform to develop new vaccines against emerging viral diseases.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29410084</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-714X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>9-10</Issue><PubDate><MedlineDate>2018 Oct - Nov</MedlineDate></PubDate></JournalIssue><Title>Microbes and infection</Title><ISOAbbreviation>Microbes Infect.</ISOAbbreviation></Journal><ArticleTitle>Measles-derived vaccines to prevent emerging viral diseases.</ArticleTitle><Pagination><MedlinePgn>493-500</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1286-4579(18)30038-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.micinf.2018.01.005</ELocationID><Abstract><AbstractText>Infectious disease epidemics match wars and natural disasters in their capacity to threaten lives and damage economies. Like SARS previously and Zika recently, the Ebola crisis in 2015 showed how vulnerable the world is to these epidemics, with over 11,000 people dying in the outbreak. In addition to causing immense human suffering, these epidemics particularly affect low- and middle-income countries. Many of these deadly infectious diseases that have epidemic potential can become global health emergencies in the absence of effective vaccines. But very few vaccines against these threats have been developed to create proven medical products. The measles vaccine is an efficient, live attenuated, replicating virus that has been safely administered to 2 billion children over the last 40 years, affording life-long protection after a single dose. Taking advantage of these characteristics, this attenuated virus was transformed into a versatile chimeric or recombinant vaccine vector with demonstrated proof-of-principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. Clinical trials have shown the safety and immunogenicity of this vaccine platform in individuals with preexisting immunity to measles. This review describes the potential of this platform to develop new vaccines against emerging viral diseases.</AbstractText><CopyrightInformation>Copyright © 2018. Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frantz</LastName><ForeName>Phanramphoei N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France; Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teeravechyan</LastName><ForeName>Samaporn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology and Cell Technology Laboratory, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Pathumthani, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangy</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur, CNRS UMR 3965, Paris, France. Electronic address: ftangy@pasteur.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Microbes Infect</MedlineTA><NlmUniqueID>100883508</NlmUniqueID><ISSNLinking>1286-4579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008458">Measles Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008458" MajorTopicYN="N">Measles Vaccine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Emerging diseases</Keyword><Keyword MajorTopicYN="Y">Measles vector</Keyword><Keyword MajorTopicYN="Y">Vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>01</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29410084</ArticleId><ArticleId IdType="pii">S1286-4579(18)30038-8</ArticleId><ArticleId IdType="doi">10.1016/j.micinf.2018.01.005</ArticleId><ArticleId IdType="pmc">PMC7110469</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2015;11(5):1258-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25901415</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2017 Sep 27;91(20):</Citation><ArticleIdList><ArticleId IdType="pubmed">28768856</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2016 Sep;17(9):1102-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27339099</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2014 Jan;101:26-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24184127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Apr 12;366(15):1423-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22494122</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vector Borne Zoonotic Dis. 2014 Oct;14(10):746-56</Citation><ArticleIdList><ArticleId IdType="pubmed">25325319</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2008 Apr 16;26(17):2164-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18346823</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Epidemiol Infect. 2010 Nov;138(11):1630-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20380769</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2014 Mar;452-453:32-41</Citation><ArticleIdList><ArticleId IdType="pubmed">24606680</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Public Health. 2016 Apr;106(4):601-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26959259</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vector Borne Zoonotic Dis. 2012 Jan;12(1):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21923274</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2001 Jul-Aug;7(4):759-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11592256</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Jan 15;191(2):207-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15609230</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2008 Dec 9;26(52):6894-900</Citation><ArticleIdList><ArticleId IdType="pubmed">18930776</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22983013</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2009 May 25;388(1):191-203</Citation><ArticleIdList><ArticleId IdType="pubmed">19345390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(11):e50397</Citation><ArticleIdList><ArticleId IdType="pubmed">23226275</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2015 May;15(5):519-27</Citation><ArticleIdList><ArticleId IdType="pubmed">25739878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12995440</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2016 Feb 27;387(10021):843-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26898855</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 2013 Jul;158(7):1445-59</Citation><ArticleIdList><ArticleId IdType="pubmed">23471635</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Nov;77(21):11546-54</Citation><ArticleIdList><ArticleId IdType="pubmed">14557640</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO J. 1995 Dec 1;14(23):5773-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8846771</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2006 Feb 20;345(2):299-304</Citation><ArticleIdList><ArticleId IdType="pubmed">16412488</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2016 Jul 30;388(10043):460-1</Citation><ArticleIdList><ArticleId IdType="pubmed">27507751</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 Jul 31;32(35):4529-36</Citation><ArticleIdList><ArticleId IdType="pubmed">24951869</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2008 Mar 15;180(6):4058-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18322215</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2017 Feb 4;389(10068):505-518</Citation><ArticleIdList><ArticleId IdType="pubmed">28017403</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2013 Oct;100(1):8-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23838047</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2015 Jun 4;33(24):2823-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25865472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Jan;86(1):317-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2911575</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1962 Nov;89:660-71</Citation><ArticleIdList><ArticleId IdType="pubmed">13990748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Epidemiol Health. 2015 Jul 21;37:e2015033</Citation><ArticleIdList><ArticleId IdType="pubmed">26212508</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2013 Dec 13;10:353</Citation><ArticleIdList><ArticleId IdType="pubmed">24330654</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viral Immunol. 2005;18(2):317-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16035943</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Aug;80(16):7929-38</Citation><ArticleIdList><ArticleId IdType="pubmed">16873250</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2013 Mar;9(3):607-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23324616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Aug 12;31(36):3718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23742993</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Oct;81(19):10597-605</Citation><ArticleIdList><ArticleId IdType="pubmed">17634218</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Vet Res. 1980 Oct;41(10):1559-64</Citation><ArticleIdList><ArticleId IdType="pubmed">7224281</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2012 Jul 15;206(2):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22551814</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Therapie. 2005 May-Jun;60(3):227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16128264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2015 Dec 10;33(50):7112-20</Citation><ArticleIdList><ArticleId IdType="pubmed">26585500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Dec 9;31(51):6079-86</Citation><ArticleIdList><ArticleId IdType="pubmed">24161574</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2010 Sep 24;28(41):6730-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20688034</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Nov;89(22):11654-67</Citation><ArticleIdList><ArticleId IdType="pubmed">26355094</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2005 Jun;2(6):e183</Citation><ArticleIdList><ArticleId IdType="pubmed">15971954</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2013;8(3):e58414</Citation><ArticleIdList><ArticleId IdType="pubmed">23516477</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2016 Jul;29(3):487-524</Citation><ArticleIdList><ArticleId IdType="pubmed">27029595</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2016 Apr 28;374(17):1635-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25629663</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2009 May 26;27(25-26):3385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19200837</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Feb;21(2):359-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25625872</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jan;78(2):834-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14694115</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2007 Nov 15;196 Suppl 2:S400-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17940976</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 May;80(9):4211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16611880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2007 Dec 12;1(3):e96</Citation><ArticleIdList><ArticleId IdType="pubmed">18160988</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2015 Aug 29;386(9996):857-66</Citation><ArticleIdList><ArticleId IdType="pubmed">26248676</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Trop Med Hyg. 2015 Aug;93(2):380-383</Citation><ArticleIdList><ArticleId IdType="pubmed">26101272</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jan;78(1):146-57</Citation><ArticleIdList><ArticleId IdType="pubmed">14671096</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2015 Dec;15(12):745-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26603900</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1993 Aug;67(8):4822-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8392616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2014 Dec 11;371(24):2249-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25289888</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2009 May 26;27(25-26):3299-305</Citation><ArticleIdList><ArticleId IdType="pubmed">19200842</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2008 Nov;4(11):e1000225</Citation><ArticleIdList><ArticleId IdType="pubmed">19043556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2009 May;5(5):e1000412</Citation><ArticleIdList><ArticleId IdType="pubmed">19412342</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccines (Basel). 2017 Sep 19;5(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">28925970</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Glob Health. 2014 Nov-Dec;80(6):444-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25960093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000A28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29410084
|texte= Measles-derived vaccines to prevent emerging viral diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29410084" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |